Sandoz, AbbVie Announce Global Resolution Of Humira Patent Disputes

Shutterstock photo

(RTTNews.com) - Sandoz, a Novartis division, announced a global resolution of all intellectual property or IP related litigation with AbbVie concerning the proposed Sandoz biosimilar Hyrimoz (adalimumab)for reference medicine Humira or adalimumab.

As per the terms of the agreement, AbbVie grants Sandoz a non-exclusive license to AbbVie's intellectual property relating to Humira(?), beginning on certain dates in certain countries in which AbbVie has intellectual property. The license period will begin on October 16, 2018 in most countries in the European Union, and on other dates in various other countries outside the US where AbbVie has IP. In the US, the license period will begin on September 30, 2023.

Sandoz will pay royalties to AbbVie for licensing its Humira patents. All litigation pending between the parties will be dismissed. AbbVie will make no payments to Sandoz. The precise terms are confidential between the parties.

Read the original article on RTTNews (http://www.rttnews.com/2942983/sandoz-abbvie-announce-global-resolution-of-humira-patent-disputes.aspx)

For comments and feedback: contact editorial@rttnews.com

This article appears in: World Markets , Stocks
Referenced Symbols: ABBV ,

More from RTT News


See All RTT news

Research Brokers before you trade

Want to trade FX?